Carlos Buesa

Oncology

Carlos Buesa, CEO of Oryzon Genomics, discusses exploring how epigenetics is reshaping the landscape of oncology and CNS therapies.

News

The UK has teamed up with Eli Lilly on initiatives, backed with £85 million in funding, to expand access to treatment for obesity.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.